SK6452003A3 - Antidiabetic compositions containing a biguanide and a sulfonamide - Google Patents

Antidiabetic compositions containing a biguanide and a sulfonamide Download PDF

Info

Publication number: SK6452003A3
Authority: SK; Slovakia
Prior art keywords: sulfonamide; biguanide; combination; pharmaceutical composition; glibenclamide
Prior art date: 2000-11-22

Application number

SK645-2003A

Other languages

English (en)

Slovak (sk)

Inventor

Nathalie Cugnardey

Nicolas Wiernsperger

Original Assignee

Merck Patent Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-11-22

Filing date

2001-10-29

Publication date

2003-09-11

2001-10-29 Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh

2003-09-11 Publication of SK6452003A3 publication Critical patent/SK6452003A3/sk

Links

229940124530 sulfonamide Drugs 0.000 title claims abstract description 22
239000003472 antidiabetic agent Substances 0.000 title claims abstract description 20
230000003178 anti-diabetic effect Effects 0.000 title claims abstract description 16
150000003456 sulfonamides Chemical class 0.000 title claims description 17
229940123208 Biguanide Drugs 0.000 title claims description 16
XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 title claims description 16
239000000203 mixture Substances 0.000 title claims description 10
229960004580 glibenclamide Drugs 0.000 claims description 38
ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 claims description 38
XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims description 33
229960003105 metformin Drugs 0.000 claims description 29
239000008194 pharmaceutical composition Substances 0.000 claims description 15
238000000034 method Methods 0.000 claims description 8
-1 4-n-butyl Chemical group 0.000 claims description 6
239000000546 pharmaceutical excipient Substances 0.000 claims description 4
BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 claims description 3
229960000346 gliclazide Drugs 0.000 claims description 3
229910052500 inorganic mineral Inorganic materials 0.000 claims description 3
150000003839 salts Chemical class 0.000 claims description 3
229960004111 buformin Drugs 0.000 claims description 2
XSEUMFJMFFMCIU-UHFFFAOYSA-N buformin Chemical compound CCCC\N=C(/N)N=C(N)N XSEUMFJMFFMCIU-UHFFFAOYSA-N 0.000 claims description 2
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
239000007788 liquid Substances 0.000 claims description 2
239000011707 mineral Substances 0.000 claims description 2
239000012764 mineral filler Substances 0.000 claims description 2
150000007522 mineralic acids Chemical class 0.000 claims description 2
231100000252 nontoxic Toxicity 0.000 claims description 2
230000003000 nontoxic effect Effects 0.000 claims description 2
150000007524 organic acids Chemical class 0.000 claims description 2
239000012766 organic filler Substances 0.000 claims description 2
229940124531 pharmaceutical excipient Drugs 0.000 claims description 2
229960003243 phenformin Drugs 0.000 claims description 2
ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 claims description 2
238000002360 preparation method Methods 0.000 claims description 2
239000007787 solid Substances 0.000 claims description 2
235000005985 organic acids Nutrition 0.000 claims 1
206010012601 diabetes mellitus Diseases 0.000 abstract description 14
238000004519 manufacturing process Methods 0.000 abstract description 5
230000001225 therapeutic effect Effects 0.000 abstract description 3
239000003937 drug carrier Substances 0.000 abstract description 2
239000003814 drug Substances 0.000 abstract 3
229940079593 drug Drugs 0.000 abstract 3
ZILVNHNSYBNLSZ-UHFFFAOYSA-N 2-(diaminomethylideneamino)guanidine Chemical compound NC(N)=NNC(N)=N ZILVNHNSYBNLSZ-UHFFFAOYSA-N 0.000 abstract 2
FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 abstract 2
241000700159 Rattus Species 0.000 description 17
230000000694 effects Effects 0.000 description 17
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
230000007423 decrease Effects 0.000 description 12
210000004369 blood Anatomy 0.000 description 9
239000008280 blood Substances 0.000 description 9
ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 9
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
229940125708 antidiabetic agent Drugs 0.000 description 7
235000012000 cholesterol Nutrition 0.000 description 7
239000008103 glucose Substances 0.000 description 7
150000003893 lactate salts Chemical class 0.000 description 6
239000002245 particle Substances 0.000 description 6
241001465754 Metazoa Species 0.000 description 5
239000003826 tablet Substances 0.000 description 5
150000003626 triacylglycerols Chemical class 0.000 description 5
102000004877 Insulin Human genes 0.000 description 4
108090001061 Insulin Proteins 0.000 description 4
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 4
238000000692 Student's t-test Methods 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
229940125396 insulin Drugs 0.000 description 4
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 3
239000013543 active substance Substances 0.000 description 3
239000003292 glue Substances 0.000 description 3
229960001052 streptozocin Drugs 0.000 description 3
239000000126 substance Substances 0.000 description 3
230000002195 synergetic effect Effects 0.000 description 3
238000012360 testing method Methods 0.000 description 3
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
229940100389 Sulfonylurea Drugs 0.000 description 2
239000000654 additive Substances 0.000 description 2
230000000996 additive effect Effects 0.000 description 2
238000010171 animal model Methods 0.000 description 2
239000002775 capsule Substances 0.000 description 2
ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 2
229960001381 glipizide Drugs 0.000 description 2
239000004310 lactic acid Substances 0.000 description 2
235000014655 lactic acid Nutrition 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
229960004329 metformin hydrochloride Drugs 0.000 description 2
OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 2
230000008447 perception Effects 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
239000000843 powder Substances 0.000 description 2
238000007619 statistical method Methods 0.000 description 2
238000003860 storage Methods 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
NVBFHJWHLNUMCV-UHFFFAOYSA-N sulfamide Chemical compound NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 description 2
YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
229920001661 Chitosan Polymers 0.000 description 1
RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 1
244000007835 Cyamopsis tetragonoloba Species 0.000 description 1
101710088194 Dehydrogenase Proteins 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
102000005548 Hexokinase Human genes 0.000 description 1
108700040460 Hexokinases Proteins 0.000 description 1
101000976075 Homo sapiens Insulin Proteins 0.000 description 1
101100533387 Homo sapiens SCGB1D1 gene Proteins 0.000 description 1
206010060378 Hyperinsulinaemia Diseases 0.000 description 1
229920002774 Maltodextrin Polymers 0.000 description 1
241000700157 Rattus norvegicus Species 0.000 description 1
102100028659 Secretoglobin family 1D member 1 Human genes 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
230000003321 amplification Effects 0.000 description 1
238000000540 analysis of variance Methods 0.000 description 1
230000002058 anti-hyperglycaemic effect Effects 0.000 description 1
210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
235000001465 calcium Nutrition 0.000 description 1
VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Substances [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
229960001761 chlorpropamide Drugs 0.000 description 1
239000008119 colloidal silica Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
239000008298 dragée Substances 0.000 description 1
230000001278 effect on cholesterol Effects 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
239000007941 film coated tablet Substances 0.000 description 1
229960004346 glimepiride Drugs 0.000 description 1
WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 1
230000010030 glucose lowering effect Effects 0.000 description 1
230000002641 glycemic effect Effects 0.000 description 1
239000008187 granular material Substances 0.000 description 1
244000144993 groups of animals Species 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
201000001421 hyperglycemia Diseases 0.000 description 1
230000003451 hyperinsulinaemic effect Effects 0.000 description 1
201000008980 hyperinsulinism Diseases 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
210000004153 islets of langerhan Anatomy 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
235000014380 magnesium carbonate Nutrition 0.000 description 1
GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
239000004137 magnesium phosphate Substances 0.000 description 1
229910000157 magnesium phosphate Inorganic materials 0.000 description 1
229960002261 magnesium phosphate Drugs 0.000 description 1
235000010994 magnesium phosphates Nutrition 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
229940126601 medicinal product Drugs 0.000 description 1
239000004005 microsphere Substances 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
239000003538 oral antidiabetic agent Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000006187 pill Substances 0.000 description 1
238000012545 processing Methods 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
230000033764 rhythmic process Effects 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000007858 starting material Substances 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
239000007940 sugar coated tablet Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
238000012353 t test Methods 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
238000010257 thawing Methods 0.000 description 1
239000010936 titanium Substances 0.000 description 1
229910052719 titanium Inorganic materials 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
230000004580 weight loss Effects 0.000 description 1
229920001285 xanthan gum Polymers 0.000 description 1
239000011701 zinc Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

SK645-2003A 2000-11-22 2001-10-29 Antidiabetic compositions containing a biguanide and a sulfonamide SK6452003A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR0015066A FR2816841B1 (fr)	2000-11-22	2000-11-22	Nouvelles compositions pharmaceutiques a action antidiabetique et leur procede de preparation
PCT/EP2001/012492 WO2002041879A2 (fr)	2000-11-22	2001-10-29	Nouvelles compositions pharmaceutiques a action antidiabetique et leur procede de preparation

Publications (1)

Publication Number	Publication Date
SK6452003A3 true SK6452003A3 (en)	2003-09-11

Family

ID=8856750

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK645-2003A SK6452003A3 (en)	2000-11-22	2001-10-29	Antidiabetic compositions containing a biguanide and a sulfonamide

Country Status (18)

Country	Link
US (1)	US20040039031A1 (fr)
EP (1)	EP1335731A2 (fr)
JP (1)	JP2004513962A (fr)
KR (1)	KR20030051858A (fr)
CN (1)	CN1474696A (fr)
AU (2)	AU2002221779A1 (fr)
BR (1)	BR0115506A (fr)
CA (1)	CA2429257A1 (fr)
CZ (1)	CZ20031449A3 (fr)
FR (1)	FR2816841B1 (fr)
HU (1)	HUP0302620A3 (fr)
MX (1)	MXPA03004431A (fr)
NO (1)	NO20032287D0 (fr)
PL (1)	PL361189A1 (fr)
RU (1)	RU2003116890A (fr)
SK (1)	SK6452003A3 (fr)
WO (2)	WO2002041879A2 (fr)
ZA (1)	ZA200304766B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2003105809A1 (fr)	2002-06-17	2003-12-24	Themis Laboratories Private Limited	Comprimes multicouche contenant des thiazolidinediones et des biguanides et procedes de production desdits comprimes
JPWO2005117855A1 (ja) *	2004-06-04	2008-04-03	興和株式会社	糖尿病の予防または治療のための薬剤
WO2007105730A1 (fr) *	2006-03-13	2007-09-20	Kyowa Hakko Kogyo Co., Ltd.	Agent ameliorant l'insulinoresistance
RU2333760C2 (ru) *	2006-05-16	2008-09-20	Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН")	Твердая дозированная лекарственная форма для лечения сахарного диабета
EP2106260B8 (fr)	2007-01-25	2018-04-04	Naia Metabolic, Inc.	Sensibilisateurs a l'iinsuline et procédés de traitement
JP2011516503A (ja) *	2008-04-07	2011-05-26	インターフェースバイオロジクス，インコーポレーテッド	細菌感染症を治療するための併用療法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2347531A1 (de) *	1973-09-21	1975-04-30	Hoechst Ag	Arzneizubereitungen zur oralen diabetes-behandlung
IT1276130B1 (it) *	1995-11-14	1997-10-27	Gentili Ist Spa	Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo
JP4278863B2 (ja) *	1997-12-08	2009-06-17	ブリストル−マイヤーズスクイブカンパニー	メトホルミンの新規塩および方法
DK0974356T3 (da) *	1998-07-15	2003-10-27	Merck Sante Sas	Tabletter omfattende en kombination af metformin og glibenclamid

2000
- 2000-11-22 FR FR0015066A patent/FR2816841B1/fr not_active Expired - Fee Related
2001
- 2001-10-29 SK SK645-2003A patent/SK6452003A3/sk unknown
- 2001-10-29 BR BR0115506-7A patent/BR0115506A/pt not_active Application Discontinuation
- 2001-10-29 HU HU0302620A patent/HUP0302620A3/hu unknown
- 2001-10-29 EP EP01997299A patent/EP1335731A2/fr not_active Withdrawn
- 2001-10-29 PL PL01361189A patent/PL361189A1/xx unknown
- 2001-10-29 KR KR10-2003-7006858A patent/KR20030051858A/ko not_active Withdrawn
- 2001-10-29 AU AU2002221779A patent/AU2002221779A1/en not_active Abandoned
- 2001-10-29 US US10/432,386 patent/US20040039031A1/en not_active Abandoned
- 2001-10-29 WO PCT/EP2001/012492 patent/WO2002041879A2/fr not_active Ceased
- 2001-10-29 CA CA002429257A patent/CA2429257A1/fr not_active Abandoned
- 2001-10-29 CZ CZ20031449A patent/CZ20031449A3/cs unknown
- 2001-10-29 CN CNA018191150A patent/CN1474696A/zh active Pending
- 2001-10-29 RU RU2003116890/15A patent/RU2003116890A/ru not_active Application Discontinuation
- 2001-10-29 JP JP2002544058A patent/JP2004513962A/ja active Pending
- 2001-10-29 MX MXPA03004431A patent/MXPA03004431A/es unknown
- 2001-11-22 WO PCT/FR2001/003697 patent/WO2002041897A2/fr not_active Ceased
- 2001-11-22 AU AU2002222026A patent/AU2002222026A1/en not_active Abandoned
2003
- 2003-05-21 NO NO20032287A patent/NO20032287D0/no not_active Application Discontinuation
- 2003-06-19 ZA ZA200304766A patent/ZA200304766B/en unknown

Also Published As

Publication number	Publication date
PL361189A1 (en)	2004-09-20
WO2002041879A3 (fr)	2003-05-22
US20040039031A1 (en)	2004-02-26
FR2816841A1 (fr)	2002-05-24
WO2002041897A3 (fr)	2003-05-30
KR20030051858A (ko)	2003-06-25
CN1474696A (zh)	2004-02-11
HUP0302620A2 (hu)	2003-11-28
NO20032287L (no)	2003-05-21
HUP0302620A3 (en)	2005-06-28
JP2004513962A (ja)	2004-05-13
AU2002222026A1 (en)	2002-06-03
WO2002041879A2 (fr)	2002-05-30
AU2002221779A1 (en)	2002-06-03
EP1335731A2 (fr)	2003-08-20
FR2816841B1 (fr)	2004-02-06
NO20032287D0 (no)	2003-05-21
WO2002041897A2 (fr)	2002-05-30
MXPA03004431A (es)	2003-08-19
CZ20031449A3 (cs)	2003-09-17
BR0115506A (pt)	2003-10-21
RU2003116890A (ru)	2004-12-10
ZA200304766B (en)	2004-09-20
CA2429257A1 (fr)	2002-05-30

Publication	Publication Date	Title
US8987244B2 (en)	2015-03-24	Preventing and/or treating cardiovascular disease and/or associated heart failure
US6376549B1 (en)	2002-04-23	Metforimin-containing compositions for the treatment of diabetes
EP1303304B1 (fr)	2008-07-09	Combinaisons pharmaceutiques pour traiter et prevenir diabetes mellitus
DE69219136T2 (de)	1997-08-28	Flüssiges nahrungsmittel, das 3-guanidinopropionsäure enthält
AU664710B2 (en)	1995-11-30	A method for treatment of metabolic disorders
EP1471902B1 (fr)	2014-07-02	Compositions pour l'utilisation dans des méthodes de traitement contre la surdité
EP0128483B1 (fr)	1990-09-12	Formes galéniques d'antidiabétiques orales et procédé de leur préparation
HRP970505A2 (en)	1998-08-31	Method of medical treatment
SK4992002A3 (en)	2003-04-01	Antidiabetic formulation and method
SK6452003A3 (en)	2003-09-11	Antidiabetic compositions containing a biguanide and a sulfonamide
US4153710A (en)	1979-05-08	N-(4-[2-(pyrazole-1-carbonamide)-ethyl]-benzenesulphonyl)-urea
EP1033129B1 (fr)	2006-06-14	Produits antimicrobiens pour traiter l'ulcère peptique
EP2001555A1 (fr)	2008-12-17	Utilisation de strobilurine pour le traitement de troubles du metabolisme du fer
EP0397646A1 (fr)	1990-11-14	Préparation pharmaceutique pour le traîtement de maladies hépatiques
EP0964678B1 (fr)	2003-03-19	Utilisation d'inhibiteurs de la comt pour fabriquer un medicament pour la prevention des dysfonctions vasculaires diabetiques
DE69626307T2 (de)	2003-10-16	Inhibitor von stickstoffmonoxid (no) synthase zur verhütung von typ ii diabetes
CA2590883A1 (fr)	2006-06-22	Composition medicinale pour le traitement du diabete
EP0868176B1 (fr)	2007-08-15	Aminoguanidine pour le traitement du diabete de type ii
US20010025053A1 (en)	2001-09-27	Use of nitric oxid synthase inhibitors for the treatment of diabetes
WO1998035667A1 (fr)	1998-08-20	Inhibiteurs de la ligase du monoxyde d'azote utilises dans le traitement des diabetes
WO2003045387A1 (fr)	2003-06-05	Composition pharmaceutique a agents actifs combines contenant de la metformine et un derive d'hydroxylamine
HK1072360B (en)	2015-01-09	Compositions for use in methods for treating hearing loss